Precipio (NASDAQ: PRPO) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.
Institutional & Insider Ownership
11.4% of Precipio shares are owned by institutional investors. Comparatively, 62.3% of Harvard Bioscience shares are owned by institutional investors. 24.7% of Precipio shares are owned by insiders. Comparatively, 9.8% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Precipio and Harvard Bioscience’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Precipio||$1.55 million||3.57||-$7.61 million||N/A||N/A|
|Harvard Bioscience||$101.88 million||1.75||-$860,000.00||$0.05||100.00|
Harvard Bioscience has higher revenue and earnings than Precipio.
This is a summary of recent ratings and price targets for Precipio and Harvard Bioscience, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Harvard Bioscience has a consensus price target of $9.00, indicating a potential upside of 80.00%. Given Harvard Bioscience’s higher possible upside, analysts clearly believe Harvard Bioscience is more favorable than Precipio.
Volatility and Risk
Precipio has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.
This table compares Precipio and Harvard Bioscience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Harvard Bioscience beats Precipio on 9 of the 11 factors compared between the two stocks.
Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.
About Harvard Bioscience
Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.